ReviewJournal of the advanced practitioner in oncology2026
Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.
Review in Journal of the advanced practitioner in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, largely because frailty complicates treatment decisions and frequently leads to the exclusion of frail patients from pivotal clinical trials. Recent subgroup analyses provide useful insight into whether quadruplet therapy may offer advantages over triplet therapy in this population. Data from the IMROZ and CEPHEUS trials were reviewed to compare outcomes between quadruplet and triplet regimens in both the overall intent-to-treat cohorts and the frailty-defined subgroups. Frailty was assessed using the International Myeloma Working Group (IMWG) frailty index in CEPHEUS and the simplified IMWG frailty score in IMROZ. Across both trials, patients with impaired performance status receiving quadruplet therapy demonstrated longer progression-free survival and higher rates of minimal residual disease negativity compared with those receiving triplet therapy. These findings suggest that quadruplet regimens may provide meaningful clinical benefit even among selected frail patients when treatment decisions are guided by comprehensive frailty assessment and individualized clinical judgment. Additional real-world evidence is needed to confirm tolerability, optimize patient selection, and further clarify the role of quadruplet therapy in this vulnerable population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.